Oncolytics Biotech has received written feedback from the United States Food and Drug Administration that could allow its ongoing REO 033 colorectal cancer study to transition directly into a pivotal expansion if initial randomized results support further development. The company is evaluating pelareorep with FOLFIRI and bevacizumab in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer, a molecularly defined population that has historically derived limited benefit from conventional immunotherapy. Oncolytics Biotech said the FDA feedback provides alignment around a potential development strategy in which objective response could support accelerated approval and progression-free survival could ultimately support full approval. The company still needs supportive Part A clinical results and a future End-of-Phase meeting before the registrational design is finalized, meaning the regulatory pathway remains conditional rather than agreed in every detail.
The development could materially shorten pelareorep’s route toward registration because REO 033 was designed from the outset as a multi-part randomized study capable of expanding without requiring Oncolytics Biotech to launch an entirely separate pivotal trial. Part A is enrolling approximately 60 patients and compares pelareorep plus standard-of-care FOLFIRI and bevacizumab with FOLFIRI and bevacizumab alone. Oncolytics Biotech expects an initial tumor-response update from Part A by the end of 2026 and has previously indicated that a supportive result could permit the pivotal expansion to begin in early 2027.
FDA feedback gives REO 033 a potentially efficient route from randomized Phase 2 data into pivotal testing
Oncolytics Biotech initially requested a Type D meeting to determine whether the existing REO 033 Part A design could support transition into a pivotal Part B and whether the expansion could form the foundation of an accelerated approval strategy. The FDA instead provided substantive written responses, after which the company decided the scheduled Type D meeting was no longer necessary and said it would pursue an End-of-Phase meeting as the program matures.
According to Oncolytics Biotech, the FDA feedback supports the potential use of response rate within an accelerated approval pathway while progression-free survival could provide the evidence required for full approval. Duration of response would also form part of the evaluation. The agency recommended a later End-of-Phase meeting to reach final agreement on important elements of the registration program, which means investors and clinicians should not interpret the August 18 update as final FDA authorization of the proposed pivotal design.
The structure is strategically valuable because Part A is randomized rather than relying solely on historical controls. Approximately 60 patients are expected to be randomized equally between pelareorep plus FOLFIRI and bevacizumab and FOLFIRI plus bevacizumab alone. Objective response is the primary clinical objective, while progression-free survival, overall survival, disease control, response duration, safety and biomarkers are among the additional measures.
If the interim results are positive, Oncolytics Biotech plans to begin Part B start-up activities quickly rather than waiting for the entire early study to conclude. This could reduce development gaps that frequently add months to oncology programs moving from proof of concept into registration-focused trials. The strategy still depends on Part A reproducing the favorable efficacy signals generated in earlier studies, making the coming randomized dataset substantially more important than the regulatory update itself.
Earlier pelareorep results showed durable responses but came from a study without the control needed for registration
The clinical rationale for REO 033 comes partly from REO 022, where pelareorep was administered with bevacizumab and FOLFIRI in second-line KRAS-mutant, microsatellite-stable metastatic colorectal cancer. Oncolytics Biotech reported an objective response rate of 33% and median response duration of 19.5 months in the relevant population. The company compared those results with historical response rates of roughly 6% to 11% and historical response duration of approximately four to six months for standard treatment.
Earlier analyses also reported median progression-free survival of 16.6 months and median overall survival of 27 months with the pelareorep-containing regimen, compared with historical estimates of 5.7 months and 11.2 months, respectively, for standard therapy. These comparisons are encouraging but inherently limited because the studies were not head-to-head trials and differences in patient selection, treatment era and other characteristics can produce misleading apparent advantages. Oncolytics Biotech itself notes that cross-study comparisons should be interpreted cautiously.
REO 033 is therefore designed to answer the question that the historical data cannot resolve. If patients randomized to pelareorep demonstrate materially higher response rates and longer disease control than the contemporary control group, Oncolytics Biotech would have a substantially stronger basis for moving directly into the proposed pivotal expansion. A weak or inconsistent difference would challenge the assumption that the unusually long responses seen previously resulted from pelareorep itself.
The upcoming Part A tumor-response update expected by year-end 2026 will consequently be the most important near-term clinical catalyst. The FDA feedback defines what a successful development route could look like, but the randomized trial will determine whether Oncolytics Biotech has the clinical evidence needed to use that route.
Pelareorep is designed to turn immunologically cold tumors into targets for a broader anticancer response
Pelareorep is an intravenously delivered double-stranded RNA immunotherapeutic agent with a proposed dual mechanism. Oncolytics Biotech says the therapy selectively replicates within tumor cells while simultaneously stimulating innate and adaptive immune activity, including inflammatory cytokine signaling, formation of tertiary lymphoid structures and expansion of tumor-infiltrating lymphocytes. The treatment has been administered to more than 1,200 patients across clinical studies.
That mechanism is particularly relevant in microsatellite-stable colorectal cancer because these tumors are commonly described as immunologically cold and generally respond poorly to checkpoint inhibition alone. Oncolytics Biotech is attempting to alter that tumor environment so the immune system becomes more capable of recognizing and attacking cancer cells while chemotherapy and bevacizumab continue providing established anticancer effects.
Translational work from earlier colorectal cancer studies has provided some support for that hypothesis. Analyses cited by Oncolytics Biotech found increased KRAS-mutant-specific T-cell populations after pelareorep treatment, suggesting enhanced immune recognition of tumor-specific mutations. The observation remains mechanistic evidence rather than proof of clinical benefit, but it supports the rationale for focusing development on RAS-mutant disease.
Pelareorep has already received FDA Fast Track designation for the second-line RAS-mutant MSS metastatic colorectal cancer population. Oncolytics Biotech also holds Fast Track designations for pelareorep programs in pancreatic and anal cancers, giving the company several gastrointestinal oncology opportunities built around the same immunotherapy platform.
ONCY shares rise modestly as investors wait for randomized data rather than regulatory guidance alone
Oncolytics Biotech shares were trading around $0.84 late Tuesday morning on August 18, up approximately 1.7% from the previous close. The stock had traded between roughly $0.83 and $0.85 during the session, while the company’s market capitalization stood near $100 million.
The relatively restrained reaction suggests investors view the FDA feedback as constructive but are not assigning major additional value before seeing the first randomized REO 033 efficacy results. That interpretation is inferred from the trading pattern rather than confirmed by market participants. The response is understandable because regulatory alignment can reduce development uncertainty, but it cannot establish that pelareorep will outperform the control arm.
Investor sentiment could change considerably when Part A reports. A meaningful response advantage accompanied by encouraging durability would strengthen both the accelerated approval argument and the commercial positioning of pelareorep in a large colorectal cancer population with limited immunotherapy options. It could also support Oncolytics Biotech’s stated efforts to pursue strategic partnerships to accelerate development.
The downside remains substantial because the earlier efficacy estimates were generated without a randomized contemporary comparator. If REO 033 produces results closer to the control arm than historical studies suggested, both the proposed pivotal expansion and the accelerated approval thesis could weaken materially.
The August 18 FDA feedback therefore provides Oncolytics Biotech with something valuable but incomplete: a potentially efficient regulatory roadmap. REO 033 can now be structured so positive randomized Part A results could lead rapidly into a pivotal Part B rather than forcing the company to start again with a separate registrational study. Whether pelareorep earns that transition will depend on the tumor-response data expected before the end of 2026.
